Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease

Trial Profile

A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BB305 beta-globin gene therapy bluebird bio (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Sponsors bluebird bio
  • Most Recent Events

    • 15 Aug 2019 Status changed from recruiting to active, no longer recruiting.
    • 14 Jun 2019 According to a bluebird bio media release, new results from patients in Group C (n=13 treated, as of 7th Mar 2019) were presented today at the 24th European Hematology Association (EHA) Congress (in Amsterdam, the Netherlands).
    • 14 Jun 2019 New results from patients in Group C (n=13 treated, as of 7th Mar 2019) presented in a bluebird bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top